John Lunec

University Name

United Kingdom

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Cell Biology

90%

Biochemistry

30%

Cancer Biology

100%

Tyrosine Kinase

40%

Genomic Instability

30%

Apoptosis

30%

Dna Damage

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles15

Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

Article Link

Year:

2024

Impact of retrotransposon protein L1 ORF1p expression on oncogenic pathways in hepatocellular carcinoma: the role of cytoplasmic PIN1 upregulation.

Article Link

Year:

2023

SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia

Article Link

Year:

2023

Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition

Article Link

Year:

2023

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.

Article Link

Year:

2023

p53 as a biomarker and potential target in gastrointestinal stromal tumors.

Article Link

Year:

2022

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

Article Link

Year:

2021

HCV Activates Somatic L1 Retrotransposition-A Potential Hepatocarcinogenesis Pathway.

Article Link

Year:

2021

Key features of the environment promoting liver cancer in the absence of cirrhosis

Article Link

Year:

2021

Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53WT Uterine Leiomyosarcoma

Article Link

Year:

2021

WIP1 Inhibition by GSK2830371 Potentiates HDM201 through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells.

Article Link

Year:

2021

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.

Article Link

Year:

2020

Co-localisation of intra-nuclear membrane type-1 matrix metalloproteinase and hypoxia inducible factor-2α in osteosarcoma and prostate carcinoma cells.

Article Link

Year:

2020

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers.

Article Link

Year:

2020

Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.

Article Link

Year:

2020

Collaborators13

Celine Cano

Reader in Medicinal Chemistry

Newcastle University

UNITED KINGDOM

Emma Haagensen

Lecturer

Newcastle University

UNITED KINGDOM

Fiona Oakley

Professor of Fibrosis Biology

Newcastle University

UNITED KINGDOM

Olivier Govaere

Tenure Track Professor

KU Leuven

BELGIUM

Santu Saha

Teesside University

UNITED KINGDOM

Geoffrey Faulkner

Professor

The University of Queensland Queensland Brain Institute

AUSTRALIA

yvette drew

Associate Professor

The University of British Columbia

CANADA

Steve Wedge

Newcastle University

UNITED KINGDOM

Tommy Martinsson

Professor

University of Gothenburg

SWEDEN

Elaine Willmore

Newcastle University

UNITED KINGDOM

Ruchi Shukla

Northumbria University

UNITED KINGDOM

Derek Mann

Professor of Hepatology

Newcastle University

UNITED KINGDOM

Craig N. Robson

UNITED KINGDOM

How do I reach out?

Meet Kite AI